{"entity":{"id":"suzette-delaloge","kind":"person","name":"Suzette Delaloge","aka":[],"tldr":"Breast medical oncologist from Gustave Roussy who chairs the board of France's Institut National du Cancer.","summary":"Suzette Delaloge is Chair (Présidente) of the Board of Directors of the Institut National du Cancer (INCa), the French national cancer agency, appointed in 2026. A medical oncologist at Gustave Roussy, she has led major breast cancer research including the MyPeBS trial of risk-based breast screening and Gustave Roussy's cancer prevention programme.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.cancer.fr/l-institut-national-du-cancer/notre-organisation/instances/conseil-d-administration"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delaloge+S%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","breast cancer","cancer policy"],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inca"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chair of the Board of Directors","institutionId":"inca","specialisms":["Breast cancer","Medical oncology","Cancer prevention and personalised screening"],"profiles":[{"label":"Institution profile","url":"https://www.cancer.fr/l-institut-national-du-cancer/notre-organisation/instances/conseil-d-administration"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delaloge+S%5BAuthor%5D"}],"papers":[{"title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆","journal":"Annals of Oncology","year":2020,"doi":"10.1016/j.annonc.2020.06.020"},{"title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","journal":"Annals of Oncology","year":2019,"doi":"10.1093/annonc/mdz012"},{"title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","journal":"New England Journal of Medicine","year":2017,"doi":"10.1056/nejmoa1706450"}]},"route":"/people/suzette-delaloge/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"institution":[{"id":"inca","kind":"institution","name":"Institut National du Cancer","route":"/institutions/inca/"}]}}